EGFR and non-small cell lung carcinoma: TRPM2 Expression is Elevated in EGFRm NSCLC Cell Lines with Acquired Resistance to Osimertinib and in Most EGFRm NSCLC Tissues Relapsed from EGFR‐TKI Treatment